| MUMBAI, July 10
MUMBAI, July 10 India's Glenmark Pharmaceuticals
Ltd is in talks with foreign companies for a
partnership on two of its biological drugs being tested for the
treatment of chronic pain and autoimmune disorders, a senior
executive said on Thursday.
Glenmark is looking for companies whose research pipelines
would complement its experimental drugs, GBR830 and GBR900,
which are both in phase 1, or early stage clinical trials on
humans, Chairman and Managing Director Glenn Saldanha said.
He declined to give names, but said he expects to find
partners by the time the two drugs complete phase 2 clinical
trials, which will be "anywhere from a year to two years."
"It will depend on whether the companies are therapeutically
focused on that area and whether they have a conflicting
molecule in their pipeline," Saldanha said in an interview at
Glenmark's headquarters in Mumbai.
While India's $15 billion pharmaceutical industry is mainly
engaged in the development and sale of generic medicines,
Glenmark is among the few that continue to invest in the
development of original medicines. Natco Pharma Ltd
and Cadila Healthcare Ltd are two other Indian
companies also involved in such research.
Glenmark has as many as many as six drugs under development
for treatments varying from pain and respiratory disorders to
multiple sclerosis, and it is already partnered with U.S.-based
Forest Laboratories Ltd and French firm Sanofi
on two of them.
Glenmark, India's sixth-largest drugmaker by sales, gets
about 34 percent of its revenue from the United States, while
India is its second-largest market, contributing a quarter of
(Editing by Matt Driskill)